Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the lymphoma working party of the European group for blood and marrow transplantation

被引:226
作者
Sureda, Anna
Robinson, Stephen
Canals, Carmen
Carella, Angela M.
Boogaerts, Marc A.
Caballero, Dolores
Hunter, Ann E.
Kanz, Lothar
Slavin, Shimon
Cornelisson, Jan J.
Gramatzki, Martin
Niederwieser, Dietger
Russell, Nigel H.
Schmitz, Norbert
机构
[1] Clinical Hematology Division, Hospital de la Santa Creu I Sant Pau, 08025 Barcelona, Antoni Maria i Claret
关键词
D O I
10.1200/JCO.2007.13.2415
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival ( OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT). Patients and Methods A total of 168 patients with HL undergoing a first alloSCT ( RIC, n = 89; myeloablative conditioning, n = 79) between January 1997 and December 2001 and registered in the European Group for Blood and Marrow Transplantation database were analyzed. Results NRM was significantly decreased in the RIC group ( hazard ratio [HR], 2.85; 95% CI, 1.62 to 5.02; P =.001). OS was better in the RIC group ( HR, 2.05; 95% CI, 1.27 to 3.29; P =.04) and there was a trend for better PFS in the RIC group ( HR, 1.53; 95% CI, 0.97 to 2.40; P =.07). RR was higher in the RIC group in univariate but not in multivariate analysis. The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS. Conclusion The lower incidence of NRM in the RIC group is encouraging, particularly because these patients experienced adverse pretransplantation characteristics more frequently. This analysis also indicates the existence of a graft-versus-HL effect correlated to the development of GVHD. Additional efforts to reduce the high RR seen in both groups of patients will be necessary to improve the modest PFS (31% v 27%) and OS (59% v 36%) for patients prepared with RIC or myeloablative conditioning.
引用
收藏
页码:455 / 462
页数:8
相关论文
共 27 条
[1]   Long-term results of blood and marrow transplantation for Hodgkin's lymphoma [J].
Akpek, G ;
Ambinder, RF ;
Piantadosi, S ;
Abrams, RA ;
Brodsky, RA ;
Vogelsang, GB ;
Zahurak, ML ;
Fuller, D ;
Miller, CB ;
Noga, SJ ;
Fuchs, E ;
Flinn, IW ;
O'Donnell, P ;
Seifter, EJ ;
Mann, RB ;
Jones, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) :4314-4321
[2]   Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].
Alvarez, I ;
Sureda, A ;
Caballero, MD ;
Urbano-Ispizzua, A ;
Ribera, JM ;
Canales, M ;
García-Conde, J ;
Sanz, G ;
Arranz, R ;
Bernal, MT ;
de la Serna, J ;
Díez, JL ;
Moraleda, JM ;
Rubió-Félix, D ;
Xicoy, B ;
Martínez, C ;
Mateos, MV ;
Sierra, J .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183
[3]   Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen [J].
Anderlini, P ;
Saliba, R ;
Acholonu, S ;
Okoroji, GJ ;
Donato, M ;
Giralt, S ;
Andersson, B ;
Ueno, NT ;
Khouri, I ;
De Lima, M ;
Hosing, C ;
Cohen, A ;
Ippoliti, C ;
Romaguera, J ;
Rodriguez, MA ;
Pro, B ;
Fayad, L ;
Goy, A ;
Younes, A ;
Champlin, RE .
BONE MARROW TRANSPLANTATION, 2005, 35 (10) :943-951
[4]   ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].
ANDERSON, JE ;
LITZOW, MR ;
APPELBAUM, FR ;
SCHOCH, G ;
FISHER, LD ;
BUCKNER, CD ;
PETERSEN, FB ;
CRAWFORD, SW ;
PRESS, OW ;
SANDERS, JE ;
BENSINGER, WI ;
MARTIN, PJ ;
STORB, R ;
SULLIVAN, KM ;
HANSEN, JA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350
[5]  
BURROUGHS LM, 2004, BIOL BLOOD MARROW S1, V73, P1
[6]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[7]   Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma [J].
Carella, AM ;
Cavaliere, M ;
Lerma, E ;
Ferrara, R ;
Tedeschi, L ;
Romanelli, A ;
Vinci, M ;
Pinotti, G ;
Lambelet, P ;
Loni, C ;
Verdiani, S ;
De Stefano, F ;
Valbonesi, M ;
Corsetti, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3918-3924
[8]  
Devetten MP, 2006, BLOOD, V108, p181A
[9]   BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients [J].
Faulkner, RD ;
Craddock, C ;
Byrne, JL ;
Mahendra, P ;
Haynes, AP ;
Prentice, HG ;
Potter, M ;
Pagliuca, A ;
Ho, A ;
Devereux, S ;
McQuaker, G ;
Mufti, G ;
Yin, JL ;
Russell, NH .
BLOOD, 2004, 103 (02) :428-434
[10]   Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease [J].
Gajewski, JL ;
Phillips, GL ;
Sobocinski, KA ;
Armitage, JO ;
Gale, RP ;
Champlin, RE ;
Herzig, RH ;
Hurd, DD ;
Jagannath, S ;
Klein, JP ;
Lazarus, HM ;
McCarthy, PL ;
Pavlovsky, S ;
Petersen, FB ;
Rowlings, PA ;
Russell, JA ;
Silver, SM ;
Vose, JM ;
Wiernik, PH ;
Bortin, MM ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :572-578